In Vitro analysis of the anti-cancer activity of mitoxantrone loaded on magnetic nanoparticles

Journal of Biomedical Nanotechnology

Volumn 9, Issue 6, 2013, Pages 1071-1075

  Lee, Kwon Jai ^a   An, Jeung Hee ^b   Chun, Je Ran ^c   Chung, Kang Hyun ^d   Park, Woo Yoon ^e   Shin, Jae Soo ^a   Kim, Dong Hee ^a   Bahk, Young Yil ^b  

^a Daejeon University   (South Korea)

^b Konkuk University   (South Korea)

^c Daejeon Health Sciences College   (South Korea)

^d Seoul National University of Science and Technology   (South Korea)

^e Chungbuk National University College of Medicine   (South Korea)

Author keywords

Endocytosis; Magnetic nanoparticle; Mitoxantrone; Prostate cancer

Indexed keywords

CHEMICAL CO-PRECIPITATION; COMPOSITE NANOPARTICLES; DRUG DELIVERY VEHICLES; ENDOCYTOSIS; MAGNETIC NANO-PARTICLES; MITOXANTRONE; PROSTATE CANCERS; THERAPEUTIC POTENTIALS;

CELL DEATH; CELL PROLIFERATION; DISEASES; DRUG DELIVERY; MOLECULAR BIOLOGY;

NANOPARTICLES;

CASPASE 3; MAGNETIC NANOPARTICLE; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; PARTICLE SIZE; PROSTATE CANCER; PROTEIN EXPRESSION; RAMAN SPECTROMETRY; WESTERN BLOTTING; X RAY DIFFRACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG THERAPY, COMBINATION; HUMANS; MAGNETITE NANOPARTICLES; MALE; MITOXANTRONE; NANOCAPSULES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84877834039     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1530     Document Type: Article

References (22)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R. C. Tiwari, A. Ghafoor, E. J. Feuer, and M. J. Thun, Cancer statistics. CA Cancer J. Clin. 55, 10 (2005).
2. C. L. Martel, P. H. Gumerlock, F. J. Meyers, and P. N. Lara, Current strategies in the management of hormone refractory prostate cancer. Cancer Treat. Rev. 29, 171 (2003).
3. C. Alexiou, W. Arnold, R. J. Kelein, F. G. Parak, P. Hulin, C. Bergemann, W. Erhardt, S. Wagenpfeil, and A. S. Lubbe, Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60, 6641 (2000).
4. G. Edan, S. Morrissey, and E. Le Page, Rationale for the use of mitoxantrone in multiple sclerosis. J. Neurol. Sci. 223, 35 (2004).
5. 3 nano particles Evaluated using an in vitro cytotoxicity assays on various tumor cell lines. Current Appl. Phys. 11 467 (2011).
6. T. Rainer S. Eveline L. Stefan and A. Christoph Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: A versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV. J. Biomed. Biotechnol. 2010, Article ID 597304 (2010).
7. A. K. Gupta and M. Gupta Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26 3995 (2005).
8. A. S. Lubbe C. Alexiou and C. Bergemann Clinical applications of magnetic drug targeting. J. Surgical Res. 95 200 (2001).
9. T. W. Flaig L. J. Su and G. Harrison International journal of cancer. J. Int. cancer 120 2028 (2007).
10. C. J. Hsiao T. K. Li Y. L. Chan L. W. Hsin C. H. Liao C. H. Lee P. C. Lyu and J. H. Guh WRC-213 an l-methionine-conjugated mitoxantrone derivative displays anticancer activity with reduced cardiotoxicity and drug resistance: Identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Biochem. Pharmacol. 75 847 (2008).
11. J. H. An and J. Seong, Proteomics analysis of apoptosis-regulating proteins in tissues with different radiosensitivity. J. Radiat. Res. (Tokyo) 47, 147 (2006).
12. G. V. M Jacintho, P. Corio, and J. C. Rubim, Surface-enhanced Raman spectra of magnetic nanoparticles adsorbed on a silver electrode. J. Electroanal Chem. 603, 27 (2007).
13. D. L. A. de Faria, S. V. Silva, and M. T. de Oliveira1, Raman microspectroscopy of some iron oxides and oxyhydroxides. J. Raman Spectrosc. 28, 873 (1997).
14. K. J. Lee, J. H. An, J. S. Shin, D. H. Kim, C. Kim, H. Ozaki, and J. G. Koh, Protective effect of maghemite nanoparticles on ultraviolet-induced photo-damage in human skin fibroblasts. Nanotechnology 18, 465201 (2007).
15. 3 nanoparticles. J. Solid State Chem. 77, 4286 (2004).
16. 3: Identification of two-magnon scattering. Phys. Rev. B 41, 7822 (1990).
17. G. Breuzarda, O. Piota, J. F. Angibousta, M. Manfaita, L. Candeilb, M. D. Riob, and J. M. Millota, Biochem. Biophys. Res. Commun. 329, 64 (2005).
18. R. S. Luo and J. Jonas, Raman scattering study of liquid ethylene glycol confined to nanoporous silica glasses. J. Raman Spectrosc. 32, 975 (2001).
19. N. Li, Y. Ma, C. Yang, L. Guo, and X. Yang, Interaction of anticancer drug mitoxantrone with DNA analyzed by electrochemical and spectroscopic methods. Biophys. Chem. 116, 199 (2005).
20. J. S. Chawla and M. M. Amiji, Cellular uptake and concentrations of tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticles. AAPS Pharmsci. 5, E3 (2003).
21. B. Han, H. Xie, Q. Chen, and J. T. Zhang, Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma. Mol. Cancer Ther. 5, 903 (2006).
22. Z. Hezeg and Z. Q. Wang, Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutation Res. 477, 97 (2001).